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Key Points 
1. Factors  associated  with  a  lower  rate of recurrent  hepa- 
titis B post-liver  transplantation  (LT) are negative  hepa- 
titis B e antigen and/or serum hepatitis B virus DNA 
pre-LT,  hepatitis D virus  superinfection,  and  fulminant 
hepatitis B. 
2. Long-term intravenous hepatitis B immune globulin 
(HBIG)  monotherapy  can  reduce  the  overall  rate of recur- 
rent  hepatitis  B to 20% to 35%. 
3. Long-term  lamivudine  monotherapy  is  associated with 
a  risk  for  drug  resistance  and  overall  3-year  rate of recur- 
rent  hepatitis  B of 40% to 50%. 
4. Combination  prophylaxis  with  HBIG  and  lamivudine 
can reduce  the  overall  rate of recurrent  hepatitis  B to 0% 
to 10%. 
5. The  dose  and  duration of HBIG therapy  needed  when 
used in combination  with  lamivudine may  be  lower,  but 
the  optimal  regimen  remains to be  determined. 
6. Lamivudine  resistance  before LT is  associated with an 
increased  risk  for  recurrent  hepatitis  B  post-LT. 
7. A cost-effective  prophylactic  regimen to prevent  recur- 
rent hepatitis B should be tailored according to risk. 
(Liver Transpl2002;8:S67-S73.) 
R esults of liver transplantation (LT) for hepatitis B in  the early 1980s were poor,  with recurrence rates 
greater than 80% and 2-year mortality rates of 50%. 
During  the past 15 years, significant advances  have been 
made  in  the management  of patients who require LT 
for hepatitis B. Using combination prophylaxis with 
hepatitis B immune globulin (HBIG)  and lamivudine, 
the rate of  recurrent hepatitis B can be reduced to less 
than 10%. However, lifelong combination prophylaxis, 
especially with a high-dose intravenous (IV) infusion of 
HBIG, is  very  expensive and  inconvenient. In addition, 
the increasing use of  lamivudine in patients awaiting 
LT will  lead to  an increased proportion  of patients with 
lamivudine resistance  before LT.  Thus, challenges for 
the  future are to establish more cost-effective prophy- 
laxis for  recurrent hepatitis B post-LT,  optimize the use 
of  lamivudine pre-LT, and develop effective prophylac- 
tic  therapy for patients who develop lamivudine resis- 
tance before LT. 
HBIG Monotherapy 
The administration  of HBIG to  prevent  recurrent  hep- 
atitis B post-LT was pioneered in Europe. Initial studies 
showed that  short-term HBIG therapy delayed, but  did 
not prevent, recurrent hepatitis B. Subsequent studies 
showed that long-term HBIG therapy significantly 
decreased the rate of recurrent hepatitis B and improved 
patient survival. The European  Concerted  Action on 
Viral Hepatitis Study reported that IV infusions of 
HBIG for longer than 6 months reduced the overall rate 
of  recurrent hepatitis B post-LT to 35%.1 Multivariate 
analysis showed that independent predictors of a lower 
rate of recurrent hepatitis B were hepatitis D virus 
(HDV) superinfection, fulminant hepatic failure, and 
negative hepatitis B e antigen (HBeAg) and hepatitis B 
virus (HBV) DNA pre-LT  (Table 1). Fulminant hepa- 
titis B frequently is accompanied by rapid clearance of 
HBV, whereas HDV superinfection has  been shown to 
suppress HBV replication. Thus,  the most important 
factor associated with a lower rate of recurrent hepatitis 
B is a low  virus load pre-LT. Pharmacokinetic studies 
showed that  the half-life of hepatitis B surface antibody 
(anti-HBs) after HBIG infbsion is shorter in patients 
who were HBeAg positive pre-LT.2 Therefore, fixed- 
dose HBIG regimens may be  insufficient to maintain 
protective anti-HBs levels in patients with a high virus 
load pre-LT. 
The  HBIG dose regimen used in most European 
centers aims to maintain trough anti-HBs titers at 
greater than 100 IU/L.  Most US centers use a fixed- 
dose regimen, with an IV infusion of 10,000 IU of 
HBIG during  the  anhepatic phase, followed  by 10,000 
IU/d  for 7 days, then 10,000 IU/mo (Table 2).  This 
regimen results in a wide range of anti-HBs titers 
among patients, as well as within patient, but most 
patients maintain  trough anti-HBs titers greater than 
500 IU/L,  and  many have trough  anti-HBs titers 
greater than 1,000 IU/L.3 The high-dose regimens  used 
in US centers have been reported to reduce the rate of 
recurrent hepatitis B to less than 20?403**; however,  these 
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Table 1. Factors Associated With Decreased Risk 
for Recurrent  Hepatitis B Post-LT 
Low virus load pre-LT 
HBeAg negative 
Undetectable serum HBV DNA 
HDV superinfection 
Fulminant hepatitis B 
regimens are very expensive (first year charges > US 
$100,000; subsequent yearly charges > US $50,000). 
In  addition, hepatitis B still recurrs at  a rate of 20% to 
30% among patients who are HBeAg and/or HBV 
DNA positive pre-LT.4 
Recurrent hepatitis B during the first 6 months 
post-LT usually is related to inadequate HBIG doses in 
patients with a high viral load pre-LT, whereas late 
recurrence is caused mainly by the selection of immune 
escape  mutants.5’6 The most common mutation involves 
a glycine to arginine  substitution at  codon  145 
(G145R) of the HBV S protein. This  mutation results 
in reduced binding  to anti-HBs and may escape neu- 
tralization by HBIG. Cessation of HBIG therapy is 
accompanied by reversion to wild-type sequence, sup- 
porting the role of HBIG in  the selection of these muta- 
tions.6 
Potential side effects of HBIG include  immune-me- 
diated reactions and anaphylaxis, mercury toxicity, and 
transmission of blood-borne infections. These side 
effects are extremely rare with current  formulations of 
HBIG, which have gone through viral inactivation 
steps and have lower protein content  and  no thimerosal 
preservative. 
Lamivudine  Monotherapy 
Prevention of Recurrent Hepatitis B Post-LT 
Lamivudine, an orally administered nucleoside ana- 
logue, is a potent  inhibitor of HBV DNA synthesis. 
Several studies showed that lamivudine  monotherapy 
Table 2. Efficacy of HBIG  Monotherapy  in Preventing 
Recurrent Hepatitis B Post-LT 
European US 
Studies Studies 
Target  trough  anti-HBs  titer  (IU/L) >l00 >500 
Recurrence rate 3 yr post-LT (Yo) 35 20 
Table 3. Efficacy of Lamivudine Monotherapy  in 
Preventing Recurrent Hepatitis B Post-LT 
UK8 N America9 Hong KonglO 
No. of patients 12 37 26 
Recurrence rate 
Post-LT (YO) 
1 -Yr 10 32 23 
3-Yr 50 41 Not available 
can prevent recurrent hepatitis B post-LT, but drug 
resistance develops with long duration of therapy 
(Table 3). The initial trial in England  reported that only 
1 of 10 patients who survived the early post-LT period 
developed recurrent hepatitis B.7 A subsequent report 
from  the same group found that 5 of 10 patients admin- 
istered lamivudine monotherapy developed recurrent 
hepatitis B because of the selection of drug-resistant 
mutants after a  median  post-LT follow-up of 966 days.* 
Two of these 5 patients  died of recurrent hepatitis B. 
In  the  North American multicenter  study, overall 1- 
and 3-year post-LT recurrence rates were 32% and 
41 %, respectively.9 One- and 3-year post-LT recur- 
rence rates were 40% (9 of 20 patients) and 60% (9 of 
15 patients) among patients  who were HBV DNA pos- 
itive before the initiation of lamivudine therapy (native 
replicators) and  18% (3 of 17 patients) and 0% (0 of 7 
patients) among patients who were HBV DNA nega- 
tive before the initiation of lamivudine therapy (native 
nonreplicators). Of the three native nonreplicators who 
were hepatitis B surface antigen (HBsAg) positive at 1 
,year post-LT,  1  patient was lost to follow-up, 1  patient 
remained HBsAg positive during  the second year, and 1 
patient became HBsAg negative during the second year. 
Thus,  the actuarial recurrence rate at 3 years post-LT 
among native nonreplicators was approximately 10% 
to 20%. 
These data confirmed the strong association be- 
tween recurrent hepatitis B post-LT and  HBV replica- 
tive status pre-LT, in particular, replicative status before 
lamivudine therapy. Although lamivudine is signifi- 
cantly more economical (charges of - US $1,80O/yr), 
current data suggest that lamivudine  monotherapy is 
not sufficient for the prevention of recurrent hepatitis B 
among native replicators. The  North American multi- 
center trial found a significantly lower, but  not zero, 
recurrence rate among patients with undetectable 
serum HBV DNA before lamivudine therapy; however, 
baseline serum HBV DNA level  was tested by means of 
a relatively insensitive assay (detection  limit, - 107 cop- 
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ies/mL). Whether lamivudine monotherapy is suffi- 
cient for the prevention of recurrent hepatitis B among 
native nonreplicators  with lower baseline serum HBV 
DNA levels  is not known. 
Contrary  to studies in Europe and  North America, a 
report  from Hong Kong  noted that only  1 of 26 
patients (58%, HBeAg positive; 35%, HBV DNA 
detected by branched DNA assay at initial evaluation) 
administered  lamivudine  monotherapy developed 
recurrent hepatitis B, defined as the reappearance of 
HBV DNA in serum.10  Five additional patients 
remained HBsAg positive, but maintained  normal ami- 
notransferase levels and mild nonspecific changes on 
liver biopsy. Thus, overall, 6 patients (23%) had recur- 
rent or persistent HBV infection post-LT during a 
median follow-up of 16 months. This study highlights 
the need to standardize the definition of recurrent hep- 
atitis B post-LT. 
Prevention of the  Need for LT 
Lamivudine has been used not only to reduce virus load 
at  the time of  LT,  but also to improve or stabilize liver 
disease in  the  hope of delaying or obviating the need for 
LT.  In  one study, 23 of 35 patients  (66%)  with  decom- 
pensated HBV-related cirrhosis who were administered 
lamivudine for more than 6 months had  improvement 
in liver function, defined as a greater than two-point 
decrease in  Child-Turcotte-Pugh  (CTP) score.' How- 
ever, 7 patients underwent LT, and 5 patients died 
during the first 6 months. Of initial responders, 2 
patients later died (1 patient, hepatocellular carcinoma; 
1  patient,  spontaneous bacterial peritonitis) and 3 
patients  subsequently developed lamivudine resistance. 
Another study reported that 14 of 23 lamivudine- 
treated patients (6 1 %) with severely decompensated 
HBV-related cirrhosis (CTP score 2 10) had improve- 
ment in CTP scores by greater than three points.12 
Compared with historic controls, treated patients were 
less likely to require LT (35% v 74%; P = .04). A third 
study of 309 North American patients  with HBV-re- 
lated cirrhosis awaiting LT found  that lamivudine treat- 
ment was not associated with overall improvement  in 
LT-free survival, but a subset of patients  had  a decrease 
in liver  disease  severity.13 
These studies showed that lamivudine therapy can 
stabilize or improve liver function and may improve 
LT-free survival. However, clinical improvement takes 
3 to 6 months. Thus, lamivudine may not be able to 
slow disease progression or reduce the need for LT in 
patients who present very late. The slow clinical effect 
argues for early initiation of lamivudine therapy; how- 
ever, the risk for resistance increases with  duration of 
treatment. Based on  the limited  data available, it seems 
that liver  disease remains stable in most patients despite 
the emergence of lamivudine-resistant mutants. How- 
ever, duration of follow-up is short, and rapidly wors- 
ening liver failure has been reported. In addition, selec- 
tion of lamivudine-resistant mutants pre-LT may 
increase the risk for recurrent hepatitis B post-LT. 
Thus,  the optimal  timing to initiate lamivudine therapy 
in  patients  with hepatitis B awaiting LT remains 
unclear. 
Combination of HBIG and  Lamivudine 
HBIG and lamivudine have different mechanisms of 
action and resistance profiles. Thus, combination  ther- 
apy  with HBIG  and lamivudine may be more effective 
than monotherapy with either agent. Several studies 
have shown that combination therapy with HBIG and 
lamivudine can reduce rates of recurrent hepatitis B to 
0% to l O%14-1s (Table 4). The largest study involved 
59 patients.14 Lamivudine therapy was initiated before 
LT in 9 of 20 patients who had detectable HBeAg 
and/or  HBV  DNA by molecular hybridization at initial 
evaluation and in 15 of the remaining 39 patients. 
HBIG was administered IV in doses of 10,000 IU dur- 
ing the anhepatic phase and then daily for 7 days,  fol- 
lowed by 10,000 IU every month. All patients remained 
HBsAg negative after a  median follow-up of 15  months 
(range, l to 60 months).  These  data suggest that com- 
bination therapy with lamivudine and high-dose IV 
HBIG may completely prevent recurrent hepatitis B 
post-LT; however, this regimen is very inexpensive. 
Other centers have reported similarly impressive 
results using lower HBIG doses.15-lS Of note, Angus et 
a l l 5  reported  a recurrence rate of only 3% among  32 
patients in Australia and  New Zealand followed up for 
a mean of 18 months (range, 5 to 45 months). In this 
study, HBIG was administered as intramuscular (IM) 
injections in doses of 400 IU (17 patients) or 800 IU 
(20 patients) daily for  the first week and  monthly there- 
after. Excellent results were achieved with less than 10% 
of HBIG doses  used in most US centers, although 50% 
of patients were HBeAg and/or HBV DNA positive 
before lamivudine treatment, 97% did  not have HDV 
superinfection, and  none had fulminant hepatitis. 
HBIG doses in other studies varied from 10,000 to 
80,000 IU  during  the first month  and  1,500  to  5,000 
IU during subsequent months.16-'s Recurrence rates 
less than 10% were reported.  These  data confirm that 
combination prophylaxis with lamivudine and HBIG 
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Table 4. Efficacy of Combination  Prophylaxis With Lamivudine and HBIG in Preventing  Recurrent  Hepatitis B Post-LT 
HBeAglHBV  HBIG Dose ( X  1,000 IU) Recurrent 
No. of DNA+ Pre-Larn* HDV/FH Pre-LT Hepatitis  B Follow-Up 
Reference Year Patients (YO) (YO) MO 1 Subsequent MO (%) (YO) (mo) 
Yao et a l l 8  1999 10 90 010 13-83 IV 1.5 IM 100 10  16 
Yoshida et all7 1999 6 G7 NNO 43 IM 4.3-6.8 IM 100 0 18 
Anguseta1I5 2000 32 50 310 1.6-3.2 IM 0.4-0.8 IM 100 3 18 
Han et a l l 4  2000 58  34 1912 80 IV 10 IV 41 0 15 
Manano  etalIG 2001 26  46 010 46.5 IV 5 IV 100 4 30 
Rosenau et all9 2001 19  52 2910 45 IV 2.3 IV 90 l l t  20 
Seehofer et a120 2001 17  100 NNO 29 IV 1.5-2 IV 1003 184 25 
Abbreviations: Lam, lamivudine therapy; NA, not available; FH, fulminant hepatitis. 
'HBV DNA by non-polymerase chain reaction- based assay or 1 O6 copies1mL or greater. 
tBoth patients  with recurrence had lamivudine resistance before LT. 
SFamciclovir therapy failed in 6 of 17 patients before lamivudine treatment. 
§All three patients with recurrence had  lamivudine resistance before LT. 
can achieve better results at lower costs than prophylaxis 
with HBIG only.  However,  the  heterogeneity of patient 
populations and  HBIC dose schedules, small number 
of patients on most  studies, and  short  duration of fol- 
low-up preclude definitive recommendations on the 
HBIG dose required  to achieve optimal results. Greater 
recurrence rates, 1  1%  and  18%, were reported  in two 
recent studies.l9.20 In  both studies,  high doses (29,000 
to 45,000 IU) of HBIG were administered  during  the 
peri-LT  period, and thereafter, HBIG was administered 
to maintain  trough  anti-HBs  titers  at greater than  100 
IU/L. The five patients  who developed recurrent  hepa- 
titis B had evidence of lamivudine resistance before LT. 
These  findings  indicate  that  combination prophylaxis 
using low maintenance doses of HBIG may not be 
sufficient to prevent recurrent hepatitis B in patients 
with  lamivudine resistance. 
Sequential Prophylaxis With HBIG Followed 
by Lamivudine 
In  attempts  to  reduce  long-term costs, several investiga- 
tors have examined  the feasibility of switching  patients 
from  lifelong HBIG therapy  to  lamivudine  therapy. In 
one study, 24 patients  who were HBeAg and/or  HBV 
DNA negative before LT  and had been administered 
HBIG for  at least 6 months were randomized  to  the 
administration of HBIG or lamivudine for l year.21 
Three patients developed recurrent  hepatitis B  (1 of 12 
patients on HBIG therapy and 2 of 12 patients on 
lamivudine  therapy). All 3 patients  entered  the  study 
within 1 year of LT.  The early recurrence (2 and 12 
weeks after  discontinuation of HBIG therapy)  in  the 
lamivudine group may be related to the presence of 
subclinical  reinfection  at  entry onto  the study; 2 
patients had detectable serum HBV DNA by liquid 
hybridization assay, and 4 patients  had  detectable 
serum HBV DNA by polymerase chain  reaction. 
In  another study, 30 patients  who were HBeAg neg- 
ative before LT were considered  for  lamivudine  substi- 
tution  after 24 months of HBIG therapy.22 None of the 
16 patients who participated in the study developed 
recurrent hepatitis B after a median follow-up of 13 
months (range, 5 to 28 months). 
These  studies suggest that  although  lamivudine 
monotherapy is insufficient as initial prophylaxis 
against recurrent  hepatitis B after LT, it may be ade- 
quate as maintenance prophylaxis in some patients. 
Further studies are needed to define this subset of 
patients and  the  optimal  timing  to  discontinue  HBIG 
therapy. 
HBV Vaccination 
The success of passive prophylaxis using HBIG suggests 
that active prophylaxis may be equally effective and 
more  economical.  However,  patients  who  require LT 
for  hepatitis B tend  to be older (>40 years), are immu- 
nosuppressed, and may not be able to  mount an ade- 
quate response to HBV vaccines. A study  from  Spain 
reported  that 14 of 17 patients (82%) developed anti- 
HBs  titers greater than 10 IU/L after one to two courses 
of  double-dose  recombinant HBV  va~cines.~3  None f 
the vaccine responders developed recurrent  hepatitis B 
during  a  median  follow-up  of 14 months (range, 3 to 50 
months),  although HBIG therapy was stopped,  lamivu- 
dine  therapy was not  initiated, and only 4 patients  had 
anti-HBs  titers greater than  100  IU/L. However, these 
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Table 5. Outcome of Patients With Lamivudine  Resistance Before LT 
No. of 
Reference Year Patients 
Saab et a125 2000 1 
Yao et all8 1999 1 




Rosenau et all9 2001 2 
Seehofer  et a120 2001 3 
Post-LT  Prophylaxis 
HBIG  (IU) Lamivudine 
Follow-Up/Time  to 
Reinfection (mo) 
IV 70,000, then 10,00O/mo Yes 
IV 80,000, then IM 1,100 every 3 wk Yes 
- Yes 
Indefinite Yes 
IV X 3 mo only Yes 
IV 40,000, then  IV  2,000 as needed Yes 







encouraging results were not confirmed in a  subsequent 
study. In this study,  only 3 of 17 Italian patients ( 1  8%) 
developed anti-HBs titers greater than 10 IU/L afier 
three courses of reinforced HBV vaccination (double 
dose or intradermal  administration) .24 Vaccination was 
commenced 4.5 months afier discontinuing HBIG 
therapy, and lamivudine was maintained throughout 
the study. Both studies enrolled patients who were 
HBeAg and serum HBV DNA negative pre-LT and 
had been administered HBIG for greater than 18 
months post-LT. The exact reason for the discrepant 
results is not clear. Further data  are needed before active 
prophylaxis can be recommended to substitute for 
HBIG. Studies of more immunogenic vaccines that 
incorporate pre-S antigens and/or more potent adju- 
van ts are  warranted. 
Prevention of Recurrent Hepatitis B 
in Patients With Lamivudine 
Resistance  Before LT 
Increasing use of lamivudine  in  patients with chronic 
hepatitis B, in particular, in patients awaiting LT, will 
lead to a  growing number of patients  with  lamivudine 
resistance before LT. To date,  there are very few data on 
the efficacy of current prophylactic therapies in patients 
with lamivudine-resistant mutants. A recent case report 
found  that indefinite  administration of high-dose IV 
HBIG, together  with  lamivudine, was  effective in pre- 
venting  recurrent hepatitis B in a  patient who had been 
followed up  to 32 months post-LT25 (Table 5) .  Other 
investigators also suggested that recurrence is not 
invariable, although the  number of patients  studied was 
small and  duration of post-LT follow-up was short.18,26 
Two studies  reported more discouraging results, with 
the 5 patients who  had lamivudine resistance pre-LT 
developing recurrent hepatitis B soon after LT despite 
the use of combination prophylaxis.19Jo Further studies 
are needed to determine  the rate of recurrent hepatitis B 
in patients with lamivudine resistance pre-LT and the 
optimal prophylactic regimen for these patients. It is 
possible that these patients may need to be maintained 
on lifelong high-dose HBIG therapy. Alternately, these 
patients may benefit from newer antiviral agents that 
are effective in suppressing the replication of lamivu- 
dine-resistant HBV. 
Role of Adefovir  Dipivoxil  and  Entecavir 
Adefovir dipivoxil and entecavir have been shown to 
have in vitro, as well as in vivo, efficacy in suppressing 
the replication of lamivudine-resistant HBV. Both 
compounds are investigational drugs. Adefovir dipiv- 
oxil was evaluated in a compassionate-use protocol in 
40 patients with lamivudine-resistant HBV awaiting 
LT and 127 patients  with  recurrent hepatitis B post-LT 
secondary to lamivudine-resistant HBV.27>28 Adefovir 
resulted in  a  mean  reduction  in  serum HBV DNA levels 
by two to three log,,, with accompanying improvement 
in liver biochemistry results. None of the patients 
awaiting LT developed significant worsening in renal 
function; however, 14% of post-LT patients had an 
increase in  serum  creatinine level greater than 0.5 
mg/dL.  Although the use of other nephrotoxic medica- 
tions, such as cyclosporine and tacrolimus, may have 
contributed to the impairment in renal function in 
post-LT patients, further  data on long-term safety are 
needed before adefovir can be used as primary prophy- 
laxis against recurrent hepatitis B. Currently,  the role of 
adefovir is mainly that of salvage therapy in patients 
with lamivudine resistance pre-LT. The efficacy of 
adefovir in this setting and dose and duration of HBIG 
required remain to be determined. Experience with 
entecavir in  transplant recipients is more  limited. Pre- 
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Risk of recurrent  hepatitis B post-LT 
High Low 
Native  replicator Native  non-replicator 
Lamivudine  resisitance  pre-LT HDV coinfection 
U 
U U 
Fulminant hepatitis B 
IV HBIG + Lamivudine  Lamivudine 
year 1 post-LT + adefovir* + perioperative HBIG 
U 
Taper HBIG 
+ Lamivudine + adefovir" 
Figure 1. Proposed  strategy  for  prophylaxis  against 
recurrent  hepatitis B post-LT  based on risk  for  recurrence. 
*, for patients with lamivudine  resistance  pre-LT. 
liminary  data suggest that entecavir is well tolerated and 
effective in  reducing  serum HBV DNA levels in 
patients  with  lamivudine resistance28;  however, further 
data are needed to establish its safety and efficacy as 
primary prophylaxis or salvage therapy. 
Cost-Effective  Prophylaxis of Recurrent 
Hepatitis B Post-LT 
Significant advances  have been made  in the prevention 
of  recurrent hepatitis B post-LT  in the past 15 years. 
Recurrent hepatitis B can be reduced to 0% to 10% by 
using combination prophylaxis with indefinite high- 
dose HBIG  and lamivudine therapy. However, this reg- 
imen is extremely  expensive and  inconvenient  to 
patients. Thus, a more cost-effective prophylactic regi- 
men  must be developed. Many investigators  have 
explored combination prophylaxis using lower dose IM 
administration  or  shorter  duration  of HBIG therapy, 
but most studies have  been limited by a small number of 
patients, short  duration of follow-up, and heterogeneity 
of patients studied.  Future endeavors should focus on 
tailoring the prophylactic regimen based on risk for 
HBV recurrence (Fig. 1). These regimens  likely  will  be 
more cost-effective than  currently used  one-size-fits-all 
approaches and will permit gradual tapering  of  prophy- 
lactic therapy over time. 
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